Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1–2 dose-confirmation studyKristina M. Brooks, Patricia M. Flynn, S. M. Ward et al.|The Lancet HIV|2023Cited by 13
Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1Hardik Chandasana, Sven C. van Dijkman, Rashmi Mehta et al.|Infectious Diseases and Therapy|2024Cited by 3
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 ResultsDwight E. Yin, S. M. Ward, Yasha Rani et al.|The Pediatric Infectious Disease Journal|2025Cited by 1